Skip to main content
The Egyptian Journal of Internal Medicine
Download PDF
  • Original article
  • Open access
  • Published:

The relationship between serum level of matrix metalloproteinase-7 and interstitial lung disease in patients with systemic sclerosis

The Egyptian Journal of Internal Medicine volume 31, pages 720–725 (2019)Cite this article

Abstract

Background

Interstitial lung disease (ILD) remains a leading cause of mortality in systemic sclerosis (SSc). Matrix metalloproteinases (MMPs) play an important role in inflammation, autoimmune diseases and aberrant fibrotic tissue remodeling.

Aim

The aim of this work was to evaluate the relation between serum level of MMP-7 and ILD in SSc patients.

Patients and methods

The study was conducted on 30 SSc patients. Pulmonary function tests and chest high-resolution computed tomography were assessed. Degree of fibrosis was assessed according to Warrick severity and extent scores. Serum level of MMP-7 was measured.

Results

The 30 patients had a mean age of 41.60±11.11 years and disease duration of 3.50 ±1.81 years; 23 with diffuse and seven with limited subtype. ILD was present in 20 patients. Serum MMP-7 was significantly higher in those with ILD (412.5±52.4 ng/ml) compared with those without (disease control group) (351.4±56.4 ng/ml) (P=0.007). In patients with ILD, MMP-7 was significantly higher in those with ground-glass opacities, honeycombing and reticular infiltration on high-resolution computed tomography; yet, it was comparable among the different grades of pulmonary restriction by pulmonary function test. There was a significant negative correlation between serum MMP-7 level and forced vital capacity and forced expiratory volume in one second (r=−0.46, P< 0.05 and r=−0.65, P< 0.0001, respectively). Correlations between MMP-7 and Warrick severity and extent were significant (P=0.002 and 0.007, respectively). MMP-7 at a cutoff value of 367.4 ng/ml was 85% sensitive and 80% specific for detection of ILD.

Conclusion

There is a strong association between serum MMP-7 and the presence, severity and extent of ILD in scleroderma patients. It might be a useful marker for ILD in SSc.

References

  1. Avouac J, Walker UA, Hachulla E, Riemekasten G, Cuomo G, Carreira PE, et al. Joint and tendon involvement predict disease progression in systemic sclerosis: a EUSTAR prospective study. Ann Rheum Dis 2016; 75:90–103.

    Google Scholar 

  2. Gheita TA, Ammar H, Kenawy SA. Potential effect of Sildenafil beyond pulmonary hypertension in a patient with diffuse systemic sclerosis and cryoglobulinemic vasculitis. Springerplus 2014; 3:559.

    Article  Google Scholar 

  3. Tarek el-G, Yasser AE, Gheita T. Coronary angiographic findings in asymptomatic systemic sclerosis. Clin Rheumatol 2006; 25:487–490.

    Article  Google Scholar 

  4. Elsayed AM, Elhefny AM, Abogabal MM, Mobasher SA, Abdelzaher A, Hassanein K, et al. Progressive systemic sclerosis in Egyptian patients: clinical characteristics and nail fold capillaroscopy. Egypt Rheumatol 2019; 41:47–51.

    Article  Google Scholar 

  5. Ismail F, Abdel-Azeem MI, Hisham Abd El-Haleem H, Mohammed A, Katta MA, Mahmoud A, et al. Feto-maternal outcome in patients with systemic sclerosis. Egypt Rheumatol 2013; 35:101–106.

    Article  Google Scholar 

  6. Farag NA, El Serougy EM, Metawee SA, El Azizi HS. Subclinical atherosclerosis and peripheral vascular disease in systemic sclerosis patients: relation to potential risk factors. Egypt Rheumatol 2015; 37:23–28.

    Article  Google Scholar 

  7. Gheita TA, Hussein H. Cartilage oligomeric matrix protein (COMP) in systemic sclerosis (SSc): role in disease severity and subclinical rheumatoid arthritis overlap. Joint Bone Spine 2012; 79:51–56.

    Article  CAS  Google Scholar 

  8. Bassyouni IH, Gheita TA, Talaat RM. Clinical significance of serum levels of sCD36 in patients with systemic sclerosis: preliminary data. Rheumatology (Oxford) 2011; 50:2108–2112.

    Article  CAS  Google Scholar 

  9. Gheita TA, Sayed S, Azkalany GS, Abaza N, Hammam N, Eissa AH. Tolllike receptor 9 in systemic sclerosis patients: relation to modified Rodnan skin score, disease severity, and functional status. Clin Rheumatol 2018; 37:757–763.

    Article  Google Scholar 

  10. Ibrahim SE, Morad CS, Farouk N, Louis A. Platelet indices as markers of inflammation in systemic sclerosis patients: relation to vascular endothelial growth factor and flow mediated dilatation. Egypt Rheumatol 2018; 40:239–242.

    Article  Google Scholar 

  11. Fawzy SM, Gheita TA, El-Nabarawy E, El-Demellawy HH, Shaker OG. Serum BAFF level and its correlations with various disease parameters in patients with systemic sclerosis and systemic lupus erythematosus. Egypt Rheumatol 2011; 33:45–51.

    Article  CAS  Google Scholar 

  12. El-Sergany M, Shahba A, Ghazy M, Bedewy MM, Bahr H, Hassan AM, et al. Increased expression of soluble fractalkine (CX3CL1) in systemic sclerosis – possible role in vascular inflammation. Egypt Rheumatol 2011; 33:93–98.

    Article  CAS  Google Scholar 

  13. Dancer RC, Wood AM, Thickett DR. Metalloproteinases in idiopathic pulmonary fibrosis. Eur Respir J 2011; 38:1461–1467.

    Article  CAS  Google Scholar 

  14. Rosas IO, Richards TJ, Konishi K, Zhang Y, Gibson K, Lokshin AE, et al. MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. PLoS Med 2008; 5:e93.

    Article  Google Scholar 

  15. Morais A, Beltrão M, Sokhatska O, Costa D, Melo N, Mota P, et al. Serum metalloproteinases 1 and 7 in the diagnosis of idiopathic pulmonary fibrosis and other interstitial pneumonias. Respir Med 2015; 109:1063–1068.

    Article  Google Scholar 

  16. Moinzadeh P, Krieg T, Hellmich M, Brinckmann J, Neumann E, Müller-Ladner U, et al. Elevated MMP-7 levels in patients with systemic sclerosis: correlation with pulmonary involvement. Exp Dermatol 2011; 20:770–773.

    Article  CAS  Google Scholar 

  17. Gheita TA, Abdel Rehim DM, Kenawy SA, Gheita HA. Clinical significance of matrix metalloproteinase-3 in systemic lupus erythematosus patients: a potential biomarker for disease activity and damage. Acta Reumatol Port 2015; 40:145–149.

    CAS  PubMed  Google Scholar 

  18. Van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis 2013; 72:1747–1755.

    Article  Google Scholar 

  19. Leroy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA, et al. Scleroderma(systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15:202–205.

    CAS  PubMed  Google Scholar 

  20. Cappelli S, Bellando Randone S, Camiciottoli G, De Paulis A, Guiducci S, Matucci-Cerinic M. Interstitial lung disease in systemic sclerosis: where do we stand? Eur Respir Rev 2015; 24:411–419.

    Article  Google Scholar 

  21. Assayag D, Kaduri S, Hudson M, Hirsch A, Baron M. High resolution computed tomography scoring systems for evaluating interstitial lung disease in systemic sclerosis patients. Rheumatology Curr Res 2012;S1:003.

  22. Warrick JH, Bhalla M, Schabel SI, Silver RM. High resolution computed tomography in early scleroderma lung disease. J Rheumatol 1991; 18:1520–1528.

    CAS  PubMed  Google Scholar 

  23. Solomon JJ, Olson AL, Fischer A, Bull T, Brown KK, Raghu G. Scleroderma lung disease. Eur Respir Rev 2013; 22:6–19.

    Article  Google Scholar 

  24. Chung L, Domsic RT, Lingala B, Alkassab F, Bolster M, Csuka ME, et al. Survival and predictors of mortality in systemic sclerosis-associated pulmonary arterial hypertension: outcomes from the pulmonary hypertension: outcomes from the pulmonary hypertension assessment and recognition of outcomes in scleroderma registry. Arthritis Care Res (Hoboken) 2014; 66:489–495.

    Article  Google Scholar 

  25. Pasarikovski CR, Granton JT, Roos AM, Sadeghi S, Kron AT, Thenganatt J, et al. Sex disparities in systemic sclerosis associated pulmonary arterial hypertension. Arthritis Rheum 2016; 18:30–33.

    Google Scholar 

  26. Manetti M, Guiducci S, Romano E, Bellando-Randone S, Conforti ML, Ibba-Manneschi L, et al. Increased serum levels and tissue expression of matrix metalloproteinase-12 in patients with systemic sclerosis: correlation with severity of skin and pulmonary fibrosis and vascular damage. Ann Rheum Dis 2012; 71:1064–1072.

    Article  CAS  Google Scholar 

  27. Hafez EA, Hamza SH, Morad CS, Abd Alkader AA. Pulmonary manifestations in a cohort of Egyptian systemic sclerosis patients. Egypt Rheumatol 2016; 40:39–44.

    Article  Google Scholar 

  28. De Oliveira Jezler SF, Santiago MB, Andrade TL, Neto CA, Braga H, Cruz AA. Interstitial lung disease in patients with progressive systemic sclerosis. J Bras Pneumol 2005; 31:300–306.

    Article  Google Scholar 

  29. Bauer Y, White ES, de Bernard S, Cornelisse P, Leconte I, Morganti A, et al. MMP-7 is a biomarker of disease progression in patients with idiopathic pulmonary fibrosis. ERJ Open Res 2017; 3:00074–2016.

    Article  Google Scholar 

  30. Sokai A, Handa T, Tanizawa K, Oga T, Uno K, Tsuruyama T, et al. Matrix metalloproteinase-10: a novel biomarker for idiopathic pulmonary fibrosis. Respir Res 2015; 16:120.

    Article  Google Scholar 

  31. Putman R, Rosas I, Hunninghake G. Genetics and early detection in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2014; 189:770–778.

    Article  CAS  Google Scholar 

  32. Limb GA, Matter K, Murphy G, Cambrey AD, Bishop PN, Morris GE, et al. Matrix metalloproteinase-1 associates with intracellular organelles and confers resistance to lamin A/C degradation during apoptosis. Am J Pathol 2005; 166:1555–1563.

    Article  CAS  Google Scholar 

  33. Pardo A, Selman M, Kaminski N. Approaching the degradome in idiopathic pulmonary fibrosis. Int J Biochem Cell Biol 2008; 40:1141–1155.

    Article  CAS  Google Scholar 

  34. Zuo F, Kaminski N, Eugui E, Allard J, Yakhini Z, Ben-Dor A, et al. Gene expression analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and humans. Proc Nat Acad Sci USA 2002; 9:6292–6297.

    Article  Google Scholar 

  35. Fujishima S, Shiomi T, Yamashita S, Yogo Y, Nakano Y, Inoue T, et al. Production and activation of matrix metalloproteinase 7 (matrilysin 1) in the lungs of patients with idiopathic pulmonary fibrosis. Arch Pathol Lab Med 2010; 134:1136–1142.

    Article  CAS  Google Scholar 

  36. Song JW, Do KH, Jang SJ, Colby TV, Han S, Kim DS. Blood biomarkers MMP-7 and SP-A: predictors of outcome in idiopathic pulmonary fibrosis. Chest 2013; 143:1422–1429.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine and Rheumatology, Faculty of Medicine, Ain Shams University, Cairo, 11311, Egypt

    Mervat M. Abo Gabal, Noha H. Shedid, Elham S. Mohamed MD & Warda Abdelfattah

Authors
  1. Mervat M. Abo Gabal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Noha H. Shedid
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Elham S. Mohamed MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Warda Abdelfattah
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Elham S. Mohamed MD.

Additional information

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Rights and permissions

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gabal, M.M.A., Shedid, N.H., Mohamed, E.S. et al. The relationship between serum level of matrix metalloproteinase-7 and interstitial lung disease in patients with systemic sclerosis. Egypt J Intern Med 31, 720–725 (2019). https://doi.org/10.4103/ejim.ejim_93_19

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.4103/ejim.ejim_93_19

Keywords